The patient with melasma who asks "can you just laser it off?" is asking a reasonable question with a complicated answer. Lasers can improve melasma. They can also make it worse — sometimes significantly worse, sometimes worse than the original problem — and the risk is not theoretical. It is well-documented across the dermatology literature, particularly in patients with Fitzpatrick IV–VI skin.
This article is not about whether melasma can be treated. It can. It is specifically about what goes wrong when laser and light-based devices are used on melasma in skin of color: the mechanisms of rebound, the wavelengths that carry the most risk, and what safer treatment sequencing looks like when the evidence supports it.
Why melasma is different from other pigment conditions
Melasma is not a spot. It is not a sun freckle that can be zapped with a single laser pulse. It is a chronic, relapsing pigment condition driven by melanocytes that are abnormally responsive to multiple triggers — UV radiation, visible light, heat, hormones, and inflammation.
The key distinction from other hyperpigmentation is that melasma involves both epidermal and dermal melanin, often with structural changes in the dermis including solar elastosis and a fragmented basement membrane. A 2025 systematic review and meta-analysis published in the Journal of Cosmetic Dermatology (available via PMC) analyzed randomized controlled trials of laser therapy for melasma and confirmed that while various laser modalities produce measurable improvement, recurrence rates are high and adverse effects — particularly post-inflammatory hyperpigmentation — remain a significant concern across Fitzpatrick types.
This structural complexity matters because it means that breaking pigment with a laser does not address the underlying melanocyte dysregulation. The melanocytes are still hyperactive. Remove the pigment today, and the same cells produce it again — often with a rebound response triggered by the inflammation the laser itself caused.
The rebound mechanism: heat, inflammation, and melanocyte memory
The most important mechanism of melasma worsening after laser treatment is post-inflammatory hyperpigmentation triggered by thermal injury. Here is the chain:
- The laser delivers energy to melanin in the skin.
- The energy converts to heat.
- Heat causes local tissue damage and releases inflammatory mediators — prostaglandins, leukotrienes, and cytokines.
- These inflammatory mediators stimulate tyrosinase activity in melanocytes.
- The melanocytes, which are already hyperactive in melasma patients, produce more melanin than before the treatment.
- The new pigment appears 2–6 weeks after treatment — often after the patient initially appeared to improve.
In Fitzpatrick IV–VI skin, this cascade is amplified. The melanocytes are more reactive, the melanosomes are larger, and the baseline melanin density means more laser energy is absorbed in the epidermis rather than reaching the deeper target. A 2024 review in the American Journal of Clinical Dermatology on new and existing treatments for melasma noted that laser and energy-based devices should be reserved for severe, non-responsive cases precisely because of the financial commitment, the risk of recurrence after treatment cessation, and the potential adverse effects including PIH.
The heat component is particularly important for melasma. Unlike UV, which triggers melasma primarily through the UVB-tyrosinase pathway, heat independently stimulates melanogenesis. A patient who sits under a hot hair dryer, takes a hot yoga class, or receives a laser treatment that raises dermal temperature can trigger melasma worsening through thermal pathways alone. This is why some melasma patients flare in summer even with strict sunscreen compliance — the ambient heat is enough.
Which lasers and light devices carry the most risk
Not all laser treatments carry equal risk for melasma in skin of color. The risk profile depends on the wavelength, pulse duration, fluence, and the degree of thermal injury produced.
Q-switched Nd:YAG 1064 nm laser toning: effective but with accumulated risk
Low-fluence QS Nd:YAG 1064 nm laser toning has been the most widely used laser approach for melasma since the concept of subcellular selective photothermolysis was introduced by Kim et al. The technique uses large spot sizes, low fluence, and repeated sessions to fragment melanosomes without destroying melanocytes. Since 2012, low-fluence QS Nd:YAG has been FDA-cleared for melasma treatment.
The mechanism is sound: the 1064 nm wavelength penetrates deeply with relatively less melanin absorption than shorter wavelengths, and the low fluence is intended to stay below the threshold that triggers significant inflammation.
But the clinical experience has revealed problems:
Rebound hyperpigmentation. A 2024 update on melasma treatments in Annals of Dermatology noted that high-fluence QS Nd:YAG carries a risk of post-inflammatory pigmentation. Even at low fluence, cumulative thermal load from repeated sessions can push melanocytes past their tolerance threshold.
Guttate hypopigmentation. A 2025 study of the 675 nm laser for melasma (published in PMC) reported that mottled hypopigmentation from low-fluence QS Nd:YAG can reach rates as high as 14%, with risk factors including short treatment intervals, higher fluence, and increased cumulative treatment sessions. This hypopigmentation can be permanent and cosmetically distressing — small white dots scattered across the treated area.
Melasma recurrence after cessation. When laser toning sessions stop, melasma returns in many patients because the underlying melanocyte dysregulation was never addressed. The American Journal of Clinical Dermatology review explicitly states that the risk of recurrence after treatment discontinuation is high.
IPL (intense pulsed light): high risk if parameters are wrong
IPL emits a broad spectrum (500–1200 nm) that includes significant energy at wavelengths absorbed by melanin. The 2024 Annals of Dermatology update on melasma treatments noted that IPL can be effective for melasma when proper parameters are used — specifically, lower fluences than those used for solar lentigines or freckles. Excessive heating of tissues worsens melasma.
For skin of color, the risk is compounded because the broadband output delivers energy across a wide range of melanin-absorbing wavelengths simultaneously. In Fitzpatrick V–VI, IPL is generally not recommended for melasma because the non-selective heating of epidermal melanin makes PIH likely.
Picosecond lasers: less heat, but not risk-free
Picosecond technology uses ultra-short pulse durations (trillionths of a second) to fragment melanin through a photoacoustic mechanism rather than a primarily photothermal one. A review in the Journal of Clinical Medicine (MDPI) noted that picosecond lasers induce melanin fragmentation through photoacoustic effects with less thermal damage to surrounding tissues, making them potentially safer than Q-switched devices.
A trial of 20 patients receiving nine sessions of 1064 nm picosecond laser at 4–6 week intervals found improvement in modified MASI scores from 10.8 to 2.7 at 6 weeks and 3.6 at 12 weeks, with no major adverse effects and no dyspigmentation.
The 730 nm picosecond laser has also shown efficacy. Han et al. (2024) published a study in Dermatologic Surgery demonstrating that low-fluence 730 nm picosecond laser was effective for melasma in Chinese patients (predominantly Fitzpatrick III–IV).
However, picosecond lasers are not risk-free for melasma in darker skin. The 675 nm laser study noted that PIH has been reported with picosecond devices as well. The American Journal of Clinical Dermatology review concluded that picosecond technology has "fewer adverse effects" than QS Nd:YAG but the evidence still favors cautious, low-fluence application in melasma.
Ablative and fractional ablative lasers: highest risk for rebound
Ablative CO2 and fractional CO2 lasers remove tissue through vaporization and produce the most intense inflammatory response of any laser category. For melasma specifically — where inflammation is the primary driver of worsening — ablative resurfacing carries the highest rebound risk.
The 2025 Journal of Cosmetic Dermatology meta-analysis included Er:YAG 2940 nm among the laser modalities studied for melasma, but the evidence for ablative and fractional ablative lasers in melasma treatment is limited precisely because the risk of triggering new pigment in a condition driven by melanocyte hyperreactivity is substantial. For skin of color, where the PIH threshold is lower, ablative resurfacing for melasma is generally avoided.
What the evidence supports for safer sequencing
The literature converges on several principles for sequencing melasma treatment in skin of color:
First line: topical therapy, always
Before any device is considered, topical therapy should be optimized and given adequate time to work. The standard approach:
- Triple combination cream (hydroquinone, tretinoin, fluocinolone acetonide) — the most evidence-backed topical regimen for melasma.
- Azelaic acid 15–20% — an alternative for patients who cannot tolerate hydroquinone, with a specific mechanism targeting hyperactive melanocytes.
- Oral tranexamic acid — growing evidence for adjunctive use at 250 mg twice daily, with monitoring for thrombotic risk.
- Strict photoprotection — SPF 50+ broad-spectrum sunscreen reapplied every 2 hours during sun exposure, plus visible-light-protective tinted formulations. Visible light (particularly blue light at 415–465 nm) independently triggers melasma through opsin-mediated melanogenesis.
These should be trialed for at least 3 months before considering device-based treatment.
If lasers are used: the safer parameters
When topical therapy fails and laser treatment is considered for refractory melasma in skin of color:
- Low-fluence QS Nd:YAG 1064 nm or picosecond Nd:YAG 1064 nm are the most evidence-supported modalities.
- Start at the lowest effective fluence and increase conservatively.
- Space sessions at least 2 weeks apart; shorter intervals increase hypopigmentation risk.
- Limit the total number of sessions. The risk of guttate hypopigmentation increases with cumulative treatment.
- Monitor for early signs of PIH after each session. If pigmentation darkens, stop.
- Continue topical therapy during and after laser sessions. Lasers are adjunctive, not standalone.
What to avoid
- High-fluence QS Nd:YAG in melasma. High fluence produces more thermal injury and higher PIH risk.
- IPL in Fitzpatrick V–VI for melasma. The broadband output is too non-selective for dark skin with hyperreactive melanocytes.
- Ablative fractional lasers for melasma in skin of color. The inflammatory response is too intense for a condition driven by inflammation-sensitive melanocytes.
- Any laser during active melasma flare. Treat during stable phases only.
Emerging approaches
The 675 nm wavelength represents a newer approach. A 2025 prospective study published in PMC evaluated the 675 nm laser for melasma in Thai patients and found no serious adverse effects — a favorable safety profile that the authors contrasted with the hypopigmentation risk of QS Nd:YAG. The 675 nm wavelength targets melanin absorption in a range that may be less prone to off-target thermal effects, but the evidence base is still early.
Combination approaches — microneedling-assisted drug delivery of tranexamic acid, non-ablative fractional lasers combined with topical agents, and RF microneedling with brightening topicals — are gaining evidence. A 2022 study compared fractional Er:YAG laser-assisted tranexamic acid delivery with and without oral tranexamic acid and found the combination superior. These approaches aim to use the device for delivery rather than for pigment destruction directly, which may reduce the thermal injury that drives rebound.
Questions to ask before pursuing laser for melasma in skin of color
- Have I tried optimized topical therapy for at least 3 months? If not, lasers are premature.
- What is my Fitzpatrick type, and does my provider have experience treating melasma with lasers at my skin type? Experience with skin of color is the single most important provider variable.
- Which laser will be used, at what fluence, and why? The answer should reference the specific device and evidence, not just "we use this for pigmentation."
- What is the plan if my melasma worsens? The provider should have a specific protocol for managing rebound.
- How many sessions are planned, and what is the endpoint? Indefinite laser toning with no endpoint is a red flag — cumulative hypopigmentation risk increases over time.
- Will I continue topical therapy during and after laser sessions? The answer should be yes. Laser-only treatment of melasma has high recurrence rates.
Sources
- The Efficacy of Laser Therapy in Melasma Treatment: A Systematic Review and Meta-Analysis. Journal of Cosmetic Dermatology, 2025. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12696807/
- An Update on New and Existing Treatments for the Management of Melasma. American Journal of Clinical Dermatology, 2024. https://link.springer.com/article/10.1007/s40257-024-00863-2
- Update on Melasma Treatments. Annals of Dermatology, 2024. https://anndermatol.org/DOIx.php?id=10.5021/ad.23.133
- Management of Melasma: Laser and Other Therapies — Review Study. Journal of Clinical Medicine (MDPI), 2024. https://www.mdpi.com/2077-0383/13/5/1468
- Efficacy and Safety of 675-nm Laser Monotherapy for Melasma. PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12872996/
- Current and New Strategies for Managing Non-Responders to Laser Toning in the Treatment of Melasma. Journal of the Korean Society for Laser Medicine and Surgery. https://www.jkslms.or.kr/journal/view.html?uid=65&vmd=Full
- Melasma treatment with the Q-switched 1,064 nm Nd:YAG laser using a novel low-fluence large spot size approach: retrospective study. Journal of the Korean Society for Laser Medicine and Surgery, 2025. https://www.jkslms.or.kr/journal/view.html?uid=377&vmd=Full
- Noninvasive Cosmetic Treatments for Fitzpatrick IV–VI: A Narrative Review. PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC13012588/
